Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Efgartigimod
Therapeutic Area: Immunology Product Name: ARGX-113
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Argenx BVBA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 23, 2020
Details:
Argenx has agreed to acquire a U.S. Food and Drug Administration (FDA) Priority Review Voucher (PRV) from Bayer Healthcare Pharmaceuticals. argenx expects to redeem the PRV for a future marketing application for its FcRn antagonist efgartigimod.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bimekizumab
Therapeutic Area: Immunology Product Name: UCB4940
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
Long-term findings from Phase 2b studies on UCB’s investigational IL-17A and IL-17F inhibitor, bimekizumab, demonstrateconsistent durability of clinical responses in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Certolizumab Pegol
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020
Details:
Four-year results from the RAPID-axSpA study of CIMZIA[®] (certolizumab pegol) highlight the importance of early, effective and long-term treatment targeting inflammation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Efgartigimod
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2020
Details:
ADAPT met its primary endpoint defined as percentage of responders on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score among acetylcholine receptor-antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) patients.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
